Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor-MedSci.cn

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a Poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Tymon-Rosario, J; Manara, P; Manavella, D; Bellone, S; Siegel, E; Hartwich, T; Harold, J; Zammataro, LA; Yang-Hartwich, Y; Mutlu, L; Altwerger, G; Menderes, G; Ratner, E; Huang, G; Clark, M; Andikyan, V; Azodi, M; Schwartz, P; Alexandrov, L; Santin, A

GYNECOLOGIC ONCOLOGY, 2022; 166 (): S30